STAAR Surgical Co. 10-Q Summary: Period Ended June 27, 2025
Business Context and Reporting Period
This filing covers the quarterly period ended June 27, 2025 (Q2 2025). STAAR Surgical Co. designs, develops, and sells implantable Collamer lenses (ICLs) for refractive surgery. The company operates as a single segment focused on ophthalmic surgical products. The reporting period reflects a significant strategic shift involving leadership realignment, cost reduction initiatives, and a substantial decline in sales volume, particularly in the China market.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Sales | $44.3 million | $99.0 million | $86.9 million | $176.4 million |
| Gross Profit | $32.8 million | $78.4 million | $60.8 million | $139.4 million |
| Gross Margin | 74.0% | 79.2% | 70.0% | 79.1% |
| Operating Income (Loss) | ($29.96 million) | $11.9 million | ($87.4 million) | $9.6 million |
| Net Income (Loss) | ($16.8 million) | $7.4 million | ($71.0 million) | $4.0 million |
| Diluted EPS | ($0.34) | $0.15 | ($1.44) | $0.08 |
| Cash and Equivalents | $167.1 million | $192.8 million (End Q2 2024) | Balance Sheet: $167.1 million (June 27, 2025) | |
| Investments (AFS) | $22.8 million | $86.3 million (Dec 27, 2024) | Balance Sheet: $22.8 million (June 27, 2025) | |
| Working Capital | $233.6 million | $297.6 million (Dec 27, 2024) | Balance Sheet: $233.6 million (June 27, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 55% in Q2 and 51% YTD compared to the prior year. This was driven primarily by a 92% drop in China sales ($5.3M vs. $63.5M in Q2) as distributors reduced purchases to deplete elevated inventory levels carried over from 2024.
- Restructuring Charges: The company incurred $5.2 million in restructuring, impairment, and related charges in Q2 (and $27.9 million YTD). These costs include $12.5 million in severance, $7.8 million in fixed asset impairments, and $4.1 million in lease impairment due to leadership realignment and facility optimization.
- Margin Compression: Gross margin declined to 74.0% (Q2) and 70.0% (YTD) from 79.2% and 79.1% respectively, attributed to lower production volumes and increased inventory reserves.
- Investment Portfolio: Investments available for sale decreased significantly from $86.3 million to $22.8 million as the company liquidated assets to maintain liquidity.
Outlook, Risks, and Unusual Items
- Merger with Alcon: On August 4, 2025, STAAR entered into a definitive agreement to be acquired by Alcon Research, LLC for $28.00 per share in cash. The transaction is subject to shareholder approval and regulatory conditions. Termination fees range from $43.4 million to $72.4 million depending on the circumstances.
- China Market Recovery: Management expects China revenue to normalize in the second half of 2025 as distributors replenish inventory. The company has implemented consignment agreements to mitigate tariff risks.
- Share Repurchases: The company initiated a $30 million share repurchase program in May 2025. It repurchased 260,515 shares for $4.5 million during Q2, with $25.5 million remaining available.
- Liquidity: Despite the net loss, the company maintains strong liquidity with $167.1 million in cash and equivalents. Operating cash flow was negative $33.0 million YTD, primarily due to the net loss and working capital changes, offset by non-cash impairment charges.
Key Investor Verification Points
- Merger Conditions: Verify the status of regulatory approvals (including China and Japan) and the likelihood of shareholder approval for the Alcon acquisition.
- China Inventory Levels: Monitor distributor inventory levels in China to confirm the anticipated sales normalization in H2 2025.
- Restructuring Completion: Confirm that the restructuring plan is fully executed and that future periods will not incur similar one-time charges.
- Tariff Impact: Assess the effectiveness of the new consignment model and Swiss manufacturing ramp-up in mitigating U.S.-China trade tariff risks.